Advertisement

Picture Fairtec GmbH We Optimise the ROI of Your Event 600x60px
Document › Details

Dynacure S.A.S.. (7/10/18). "Press Release: Dynacure Names Chris Freitag (MD) Chief Medical Officer". Strasbourg.

Organisations Organisation Dynacure S.A.S.
  Organisation 2 Debiopharm International S.A.
  Group Debiopharm (Group)
Products Product Dyn101 antisense oligonucleotide drug (Dynacure / Ionis)
  Product 2 clinical research
Persons Person Freitag, Chris (Dynacure 201807– CMO before Debioparm + BTG plc + Shire + Roche)
  Person 2 van Rooijen, Stephane (Dynacure 201807 CEO before Confo Therapeutics –201609 CEO STEPPED DOWN 9/16)
     


Dynacure, a biotechnology company developing new treatments for patients affected by serious orphan disorders, announced today the expansion of its leadership team with the appointment of Chris Freitag (MD) as Chief Medical Officer.

He will be responsible for the company’s medical strategy, clinical operations and expand Dynacure’s network with medical and academic organizations. “I’m excited to join Dynacure and build a solid clinical and regulatory development strategy supporting Dynacure’s lead program in centronuclear myopathy (CNM) and other indications”, said Chris Freitag.

Dr Freitag obtained his medical degree from Kiel University, Germany in 1994. He started his career in the pharmaceutical industry at Roche in pharmacovigilance and medical affairs. At Shire, he held several positions in clinical development and medical affairs, covering the internal medicine portfolio, finally as VP, Global Clinical development and Innovation. In 2014 he joined BTG plc in the UK as SVP to head up Vascular Medicine and moved on to become responsible for global clinical development across the portfolio. He joined Debiopharm International SA in 2016 to lead the clinical R&D function managing international drug development across Phase I to III. Recently, he joined Dynacure as Chief Medical Officer where he is responsible for medical and regulatory strategy, including clinical development of the lead compound in CNM.

“I’m delighted to welcome Chris to the management team. The addition of Dr Freitag ensures the rapid advancement of our CNM program being the foundation for future growth of Dynacure”, said Stephane van Rooijen, chief executive officer of Dynacure.

Dynacure’s lead drug program, Dyn101, is an antisense oligonucleotide therapy in development for the rare and often fatal muscle disease centronuclear myopathy. Dyn101 is being developed in collaboration with Ionis Pharmaceuticals, the leading biopharmaceutical company in RNA-targeted drug discovery.

Centronuclear myopathies are a group of rare genetic muscular disorders ranging in impact from mild to severely affected, with symptoms manifesting from birth to late adulthood. Muscle weakness can affect ambulation to the point of requiring wheelchair use, respiratory muscle weakness often needs ventilatory assistance, and difficulty swallowing may require a gastric tube to ensure adequate nutrition. Dyn101 targets two forms of CNM: X-linked (the most common variant) and the autosomal dominant form.

   
Record changed: 2018-07-18

Advertisement

Picture [iito] – Putting Information into Context 600x102px

More documents for Dynacure S.A.S.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px




» top